Toronto Dominion Bank Grows Position in Agilent Technologies, Inc. (A)

Toronto Dominion Bank lifted its holdings in Agilent Technologies, Inc. (NYSE:A) by 25.5% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 109,280 shares of the medical research company’s stock after acquiring an additional 22,216 shares during the period. Toronto Dominion Bank’s holdings in Agilent Technologies were worth $6,480,000 as of its most recent filing with the SEC.

Other hedge funds have also added to or reduced their stakes in the company. BlackRock Inc. grew its stake in Agilent Technologies by 1,946.9% during the first quarter. BlackRock Inc. now owns 23,119,219 shares of the medical research company’s stock worth $1,222,310,000 after buying an additional 21,989,739 shares in the last quarter. JPMorgan Chase & Co. grew its stake in Agilent Technologies by 45.2% during the second quarter. JPMorgan Chase & Co. now owns 12,145,610 shares of the medical research company’s stock worth $720,358,000 after buying an additional 3,779,099 shares in the last quarter. PNC Financial Services Group Inc. grew its stake in Agilent Technologies by 720.6% during the second quarter. PNC Financial Services Group Inc. now owns 1,131,276 shares of the medical research company’s stock worth $67,097,000 after buying an additional 993,414 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. acquired a new stake in Agilent Technologies during the second quarter worth about $58,693,000. Finally, Voya Investment Management LLC grew its stake in Agilent Technologies by 444.0% during the second quarter. Voya Investment Management LLC now owns 1,032,128 shares of the medical research company’s stock worth $61,215,000 after buying an additional 842,398 shares in the last quarter.

In related news, CFO Didier Hirsch sold 1,200 shares of the company’s stock in a transaction that occurred on Wednesday, September 13th. The stock was sold at an average price of $66.00, for a total transaction of $79,200.00. Following the completion of the transaction, the chief financial officer now owns 164,202 shares in the company, valued at $10,837,332. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Michael R. Mcmullen sold 16,492 shares of the company’s stock in a transaction that occurred on Thursday, September 14th. The shares were sold at an average price of $65.33, for a total value of $1,077,422.36. Following the transaction, the chief executive officer now owns 211,872 shares of the company’s stock, valued at approximately $13,841,597.76. The disclosure for this sale can be found here. Insiders sold 165,720 shares of company stock valued at $10,488,739 in the last quarter.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark law. The correct version of this piece of content can be read at https://stocknewstimes.com/2017/10/19/toronto-dominion-bank-grows-position-in-agilent-technologies-inc-a.html.

Shares of Agilent Technologies, Inc. (NYSE A) traded down 0.42% on Thursday, reaching $66.16. 109,526 shares of the company were exchanged. The firm has a market capitalization of $21.29 billion, a PE ratio of 34.12 and a beta of 1.30. The stock’s 50-day moving average is $65.56 and its 200 day moving average is $60.25. Agilent Technologies, Inc. has a 12-month low of $42.92 and a 12-month high of $67.82.

Agilent Technologies (NYSE:A) last announced its quarterly earnings data on Tuesday, August 15th. The medical research company reported $0.59 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.52 by $0.07. Agilent Technologies had a return on equity of 16.95% and a net margin of 14.36%. The firm had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.09 billion. During the same quarter in the previous year, the company posted $0.49 earnings per share. The business’s revenue was up 6.7% on a year-over-year basis. On average, analysts forecast that Agilent Technologies, Inc. will post $2.32 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 25th. Shareholders of record on Tuesday, October 3rd will be given a $0.132 dividend. The ex-dividend date of this dividend is Monday, October 2nd. This represents a $0.53 annualized dividend and a yield of 0.79%. Agilent Technologies’s payout ratio is currently 27.32%.

A has been the topic of a number of analyst reports. Deutsche Bank AG reiterated a “buy” rating and set a $66.00 price objective on shares of Agilent Technologies in a research note on Thursday, June 22nd. Morgan Stanley reiterated an “overweight” rating on shares of Agilent Technologies in a research note on Monday, July 10th. BidaskClub upgraded shares of Agilent Technologies from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, July 11th. Wells Fargo & Company upgraded shares of Agilent Technologies from a “market perform” rating to an “outperform” rating and increased their price objective for the stock from $42.92 to $60.73 in a research note on Wednesday, July 12th. Finally, Barclays PLC reiterated a “buy” rating and set a $67.00 price objective on shares of Agilent Technologies in a research note on Wednesday, July 19th. Four equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $65.12.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.

Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies, Inc. (NYSE:A).

Institutional Ownership by Quarter for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply